


## L162389

<b>Cat. No.:</b>	HY-101618
<b>CAS No.:</b>	169281-53-2
<b>Molecular Formula:</b>	C <sub>31</sub> H <sub>38</sub> N <sub>4</sub> O <sub>4</sub> S
<b>Molecular Weight:</b>	562.72
<b>Target:</b>	Angiotensin Receptor
<b>Pathway:</b>	GPCR/G Protein
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	L162389 is a potent antagonist of angiotensin AT1 receptor with K <sub>i</sub> of 28 nM.
<b>IC<sub>50</sub> &amp; Target</b>	Ki: 28 nM (angiotensin AT1 receptor) <sup>[1]</sup>
<b>In Vitro</b>	L-162,389 stimulates phosphatidylinositol turnover, albeit only to a small percentage of the angiotensin response. L-162,389 acts as angiotensin antagonist with IC <sub>50</sub> value of 105 nM <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### PROTOCOL

<b>Kinase Assay</b> <sup>[1]</sup>	Monoiodinated <sup>125</sup> I-[Sar1,Leu8]angiotensin II is prepared by the Iodo-Gen method. One day after transfection and 24 hr before the binding experiments, the transfected cells are transferred to 6-, 12-, or 24-well culture plates, with 0.15-9 × 10 <sup>5</sup> cells/well, with a goal of total binding of 5-10% of the radiolabeled peptide. The cells are washed twice with buffer (25 mM Tris, 5 mM MgCl <sub>2</sub> , 140 mM NaCl, pH 7.4) before and after the binding. The binding is carried out for 24 hr at 4°C with 50 pm <sup>125</sup> I-[Sar1,Leu8]angiotensin II and variable amounts of unlabeled nonpeptide or peptide ligands in 0.5-1 mL of a 25 mM Tris buffer containing 5 mM MgCl <sub>2</sub> , pH 7.4. The binding data are analyzed by computerized nonlinear regression analysis using InPlot 4.0. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
------------------------------------	---

### REFERENCES

[1]. Perlman S, et al. Dual agonistic and antagonistic property of nonpeptide angiotensin AT1 ligands: susceptibility to receptor mutations. Mol Pharmacol. 1997 Feb;51(2):301-11.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA